InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
16 hedge funds and large institutions have $1.32M invested in InVivo Therapeutics Holdings Corp in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
16% less funds holding
Funds holding: 19 → 16 (-3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
27% less capital invested
Capital invested by funds: $1.81M → $1.32M (-$491K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$29K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.22K |
| 4 |
ICM
IMS Capital Management
Portland,
Oregon
|
+$6.6K |
| 5 |
Millennium Management
New York
|
+$6.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$394K |
| 2 |
VF
Virtu Financial
New York
|
-$33K |
| 3 |
Goldman Sachs
New York
|
-$30K |
| 4 |
Morgan Stanley
New York
|
-$14.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.49K |
NVIV Hedge Fund Activity: Q3 2021 in Review
16 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2021, worth a combined $1.32M — down 27% from $1.81M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NVIV and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $29K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $394K sold.
- 16 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2021, down from 19 in Q2 2021.
- Funds reported $1.32M of InVivo Therapeutics Holdings Corp stock for Q3 2021, down 27% quarter-over-quarter.
- 3 funds opened new InVivo Therapeutics Holdings Corp positions in Q3 2021 and 6 closed out, a net change of -3 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q3 2021 was Two Sigma Securities, an estimated $29K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q3 2021 was Renaissance Technologies, an estimated $394K sold.
Based on aggregated 13F filings for Q3 2021.